Home / Private raises / Gossamer Bio, Inc.
Gossamer Bio, Inc.
Biotechnology · San Diego, California · $25.0M sold across 1 offering
Form D filings (1)
| Filed | Form | Sold | Offered | Investors | Exemption | Securities | First sale | |
|---|---|---|---|---|---|---|---|---|
| 2026-09-04 | D (new) | $25.0M | $150M | 38 | 506(b) | Options/warrants, Security to be acquired | Aug 20 | SEC ↗ |
An update (D/A) restates the running total of its offering, so the total above counts each offering's latest figure once.
Sold through (placement agents)
| Broker-dealer | Solicited in |
|---|---|
| Leerink Partners LLC | All States |
| Cantor Fitzgerald & Co. | All States |
Sales commissions $1.4M in the latest filing.
Issuer
| Industry | Biotechnology |
| Located | San Diego, California |
| Entity | Corporation |
| Incorporated | Delaware |
| SEC CIK | 1728117 |
People named in the latest filing
| Name | Role |
|---|---|
| Faheem Hasnain | Executive Officer, Director |
| Russell Cox | Director |
| Thomas Daniel | Director |
| Skye J. Drynan | Director |
| Sandra Milligan | Director |
| Steven D. Nathan | Director |
| John Quisel | Director |
| Bryan Giraudo | Executive Officer |
| Christian Waage | Executive Officer |
| Robert Smith | Executive Officer |
| Caryn Peterson | Executive Officer |
Names and roles as filed with the SEC. Addresses are not shown.
Source: SEC EDGAR Form D filings. Amounts are self-reported by the issuer. Not investment advice.
How are we doing?
